Prof. Matthias Tschöp
“The Helmholtz Pioneer Campus converts a groundbreaking vision for world-leading multidisciplinary metabolism research”.
Prof. Vasilis Ntziachristos
“Linking top talents in projects and goals,
the Helmholtz Pioneer Campus creates
an unprecedented bioengineering elite.”
At the Helmholtz Pioneer Campus, exceptional talents from various scientific fields share their expertise to solve the most important biomedical challenges of our time. The campus creates a unique atmosphere for interdisciplinary collaboration in an ideally equipped, creative and dynamic environment, beyond hierarchies and administrative hurdles. Our commitment to highest scientific standards and unlimited enthusiasm draws upon the best and most imaginative scientists.
The Helmholtz Pioneer Campus organizational culture thrives on
- scientific freedom and creativity
- bold collaboration across disciplines- pursuit of serendipitous discoveries
- accelerated translation of new discoveries for precision medicine and health
- a global perspective on science and inspiration for future scientists
The Helmholtz Pioneer Campus is a catalyst for decisive breakthroughs in biology and medicine. Focused on bioengineering and metabolic disease mechanisms, it supports the next generation of international research leaders and encourages scientific vision. Offering top tier resources for young, up and- coming scientists, the campus catalyzes interdisciplinary teamwork towards (but not limited to)
- new approaches for personalized medicine in prevention, diagnosis and therapy
- novel biomarkers and biosensors for the early identification and improved monitoring of diseases
- seamless integration of basic discovery, bio-engineering and clinical application
- rapid translation of innovative results into IP, licensing and new ventures
V. Ntziachristos, D. Razansky - Bridging technologies:
Optoacoustic tomography combines the specificity of optical imaging with the penetration and spatiotemporal resolution of ultrasound. MSOT (multispectral opto-acoustic tomography) enables non-invasive and quantitative diagnostics, and facilitates real-time precision surgery.
M. H. Tschöp - Breakthroughs in drug-development:
The novel, anti-obesity & anti-diabetic synthetic peptides combine the functional entities of up to three physiological hormones, a concept called ‘unimolecular polypharmacy’. Iterative cycles of medicinal chemistry, in-vivo pharmacology and functional testing require trusted partnerships across academic- and corporate partners.
H. Lickert, F. Theis, M. Meier – Challenging stem cell concepts:
Determining stem- and progenitor cell heterogeneity, -plasticity and mechanisms of lineage choice requires the seamless integration of state of the art genetic-, single cell -omics, computational-, 3D-mini organ- and microfluidic 'on-chip’ technologies.
(1) HPC will embrace the human organoid-technology (3-dimensional, human ‘organs in a dish’) to model human physiology and disease, and reveal so far un-accessible molecular-metabolic routes for therapeutic intervention.
(2) Organoids offer unprecedented opportunities for the development and testing of new molecular probes, biosensors, synthetically engineered molecular circuits, imaging- and optical devices etc.; organoids promise to close the translational gap and complement existing in-vivo models, in particular the exceptional resources and expertise at the GMC.
(3) The synthesis of biomedical-, engineering-, bio-sensing and imaging expertise puts
HPC in a prime position to address relevant aspects of the ‘big-data’ revolution.